Byungwoo Ryu, Ph.D.
Director of Biomarker Research Program
Boston University School of Medicine, Dept of Dermatology
609 Albany Street, J-502
Boston, MA 02118
T: (617) 638-5535
Dr. Ryu joined the Department of Dermatology at the Boston University of School of Medicine as an assistant Professor in 2011. He received his Ph.D. degree from Oregon State University in Molecular Toxicology. Dr. Ryu completed his postdoctoral fellowships at the National Cancer Institute in Bethesda, Maryland and Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine, Baltimore, Maryland. Dr. Ryu served as an assistant member of the Nevada Cancer Institute at Las Vegas, Nevada and clinical assistant professor of medicine at the University of Nevada School of Medicine at Reno, Nevada. Dr. Ryu is a recipient of Howard Temin Award, career development award (K01), from the National Cancer Institute.
Current Research Interests
Dr. Ryu’s research interest is to determine the molecular events that dictate melanoma tumorigenicity and malignant progression. It is likely that identification of such molecular pathways will allow us to identify clinically useful biomarkers as well as potential therapeutic targets against this lethal form of skin cancer.
Biomarkers for melanoma progression: Dr. Ryu’s laboratory currently focuses on discovery of molecular biomarkers that can be used for patient stratification and personalized therapy. His laboratory uses genomic and molecular profiling techniques on tissue and blood samples from melanoma patients to find patterns of molecular signatures and correlate them with clinical outcomes.
Therapeutic targeting of metastasis-initiating cells (MICs): Despite recent progress, the molecular mechanisms of tumor metastasis remain unclear. Isolation and dissection of the MICs, subpopulation of tumor cells including circulating cancer cells in patient’s blood, will shed light on the molecular events of metastasis progression. Dr. Ryu’s laboratory focuses on the genetic and epigenetic characterization of the MICs as well as developing therapeutic and preventive strategies of cancer metastasis by targeting the MICs.
- Ryu B, Moriarty WF, Stine MJ, DeLuca A, Kim DS, Meeker AK, Grills LD, Switzer RA, Eller MS, Alani RM. Global analysis of BRAFV600E target genes in human melanocytes identifies matrix metalloproteinase-1 as a critical mediator of melanoma growth. J Invest Dermatol. 2011 Jul;131(7):1579-83.
- Stine MJ, Wang CJ, Moriarty WF, Ryu B, Cheong R, Westra WH, Levchenko A, Alani RM. Integration of genotypic and phenotypic screening reveals molecular mediators of melanoma-stromal interaction. Cancer Res. 2011 Apr 1;71(7):2433-44. Epub 2011 Feb 15.
- Kim HE, Symanowski JT, Samlowski EE, Gonzales J, Ryu B. Quantitative measurement of circulating lymphoid-specific helicase (HELLS) gene transcript: a potential serum biomarker for melanoma metastasis. Pigment Cell Melanoma Res. 2010 Dec;23(6):845-8.
- Ryu B, Kim DS, Deluca AM, Alani RM. Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression.PLoS One. 2007 Jul 4;2(7):e594.